Human gingiva-derived mesenchymal stem cells are therapeutic in lupus nephritis through targeting of CD39
5'-Nucleotidase
/ antagonists & inhibitors
Animals
Antigens, CD
/ metabolism
Apyrase
/ antagonists & inhibitors
B-Lymphocytes
/ immunology
Cell Differentiation
/ immunology
Cell Proliferation
Cells, Cultured
Coculture Techniques
Disease Models, Animal
Female
GPI-Linked Proteins
/ antagonists & inhibitors
Gingiva
/ cytology
Humans
Lupus Nephritis
/ immunology
Lymphocyte Activation
Mesenchymal Stem Cell Transplantation
Mesenchymal Stem Cells
/ immunology
Mice
Plasma Cells
/ immunology
Primary Cell Culture
RNA-Seq
Signal Transduction
/ drug effects
Single-Cell Analysis
Autoimmune diseases
B cells
CD39(−)CD73 signaling pathway
GMSCs
Journal
Journal of autoimmunity
ISSN: 1095-9157
Titre abrégé: J Autoimmun
Pays: England
ID NLM: 8812164
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
08
01
2020
revised:
30
04
2020
accepted:
18
05
2020
pubmed:
23
6
2020
medline:
12
10
2021
entrez:
23
6
2020
Statut:
ppublish
Résumé
Cell specific and cytokine targeted therapeutics have underperformed in systemic lupus erythematosus (SLE). Mesenchymal stem cells (MSCs) have emerged as a novel therapy to address the dysregulation in autoimmune diseases but also have limitations. Human gingiva derived MSCs (GMSCs) are superior in regulating immune responses. Here, we demonstrate that the adoptive transfer of GMSCs homes to and maintains in the kidney and has a robust therapeutic effect in a spontaneous lupus nephritis model. Specifically, GMSCs limits the development of autoantibodies as well as proteinuria, decreases the frequency of plasma cells and lupus nephritis histopathological scores by directly suppressing B cells activation, proliferation and differentiation. The blockage of CD39
Identifiants
pubmed: 32565049
pii: S0896-8411(20)30109-8
doi: 10.1016/j.jaut.2020.102491
pii:
doi:
Substances chimiques
Antigens, CD
0
GPI-Linked Proteins
0
5'-Nucleotidase
EC 3.1.3.5
Nt5e protein, mouse
EC 3.1.3.5
Apyrase
EC 3.6.1.5
CD39 antigen
EC 3.6.1.5
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
102491Subventions
Organisme : NIAMS NIH HHS
ID : R01 AR059103
Pays : United States
Informations de copyright
Copyright © 2020. Published by Elsevier Ltd.